Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Reexamination Certificate
2006-01-10
2006-01-10
Kunz, Gary (Department: 1616)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
C424S450000, C514S075000, C514S102000, C514S824000, C514S951000
Reexamination Certificate
active
06984400
ABSTRACT:
A method of treating or preventing restenosis by administering to an individual an effective amount of an active ingredient comprising a bisphosphonate particle or a bisphosphonate particulate. The bisphosphonate may be encapsulated, embedded or adsorbed within the particle, dispersed uniformly in the polymer matrix, adsorbed on the particle surface, or in combination of any of these forms. The particles include liposomes or inert polymeric particles, such as microcapsules, nanocapsules, nanoparticles, nanospheres, or microparticles. The particulates include any suspended or dispersed form of the bisphosphonate which is not encapsulated, entrapped, or adsorbed within a polymeric particle. The particulates include suspended or dispersed colloids, aggregates, flocculates, insoluble salts and insoluble complexes of the active ingredient. The active ingredient effects restenosis by inhibiting the growth and proliferation of the cell types involved in the restenotic cascade, such as macrophages/monocytes, fibroblasts and smooth-muscle cells.
REFERENCES:
patent: 4067971 (1978-01-01), Francis et al.
patent: 4216211 (1980-08-01), Francis
patent: 5096717 (1992-03-01), Wirth et al.
patent: 5196409 (1993-03-01), Breuer et al.
patent: 5312954 (1994-05-01), Breuer et al.
patent: 5338731 (1994-08-01), Breuer et al.
patent: 5492926 (1996-02-01), Cullinan et al.
patent: 5652227 (1997-07-01), Teronen et al.
patent: 5733564 (1998-03-01), Lehtinen
patent: 5741514 (1998-04-01), Barenholtz et al.
patent: 5760030 (1998-06-01), Bryant et al.
patent: 5776429 (1998-07-01), Unger et al.
patent: 5792885 (1998-08-01), Ham et al.
patent: 5882656 (1999-03-01), Bechard et al.
patent: 5932563 (1999-08-01), Stokes et al.
patent: 5932580 (1999-08-01), Levitzki et al.
patent: 5994341 (1999-11-01), Hunter et al.
patent: 6139871 (2000-10-01), Hope et al.
patent: 2002/0192157 (2002-12-01), Low et al.
patent: 196 37 890 (1998-03-01), None
patent: 0 339 237 (1989-11-01), None
patent: 0459 318 (1991-12-01), None
patent: 97 33552 (1997-09-01), None
patent: WO 97/43437 (1997-11-01), None
patent: WO 88 00289 (1998-02-01), None
patent: 98 31359 (1998-07-01), None
patent: 99 38998 (1999-08-01), None
patent: 00 21540 (1999-10-01), None
patent: 00 34293 (2000-06-01), None
patent: 00 64516 (2000-11-01), None
Patashnik et al, J. Drug Target, Preparation and Evaluation of chitosan microspheres containing bisphosphonates, 1997, 4(6):371-80).
Monkkonen et al, Calcif Tissue Int., vol. 53, 1993.
Makkar et al (J. Cardiovascular Pharmacology Therapy, Apr. 1996, 1(2): 177-188).
Rubin et al., “Cellular and Molecular Mechanisims of Radiation Inhibition of Restenosis. Part I: Role of the Macrophage and Platelet-Derived Growth Factor”,Int. J. Radiation Oncology Biol. Phys.(1998), vol. 40, pp. 929-941.
Monkkonen et al., “Studies on Liposome Formulations for Intra-articular Delivery of Clodronate”,Journal of Controlled Release,(1995), vol. 35, pp. 145-154.
Abstract, Kunitomo et al., “Experimental Induction of Athero Sclerosis in Guinea-Pigs Fed a Cholesterol Vitamin D-2-Rich Diet”, (1983).
Mönkkönen et al., “The Effect of Liposome-Encapsulated and free Clodronate on the Growth of Macrophage-like Cells In Vitro: The Role of Calcium and Iron”,Calcif. Tissue International,(1993), vol. 53, pp. 139-146.
Gennaro, “Parenteral Preparations”,Remington: The Science and Practice of Pharmacy,20thEdition, Chapter 41, pp. 780-920.
Kramsch et al., “Th effect of Agents Interfering with Soft Tissue Calcification and Cell Proliferation on Calcific Fibrous-Fatty Plaques in Rabbits”,Circulation Research,(1978), vol. 42, No. 4, pp. 562-570.
Mönkkönen et al., “Growth Inhibitions of Macrophage-Like and Other Cell Types by Liposome-Encapsulated, Calcium-Bound, and Free Bisphosphonates In Vitro”,Journal of Drug Targeting,(1994), vol. 2, pp. 299-308.
Fleisch, “Bisphosphonates in bone disease”Parthenon Publishing Group Inc.,(1997), pp. 184-210.
Mak et al., “Clinical Trials to prevent Restenosis after Precutaneous Coronary Revescularization”,The NY Academy of Sciences,(1994), pp. 225-277.
LeClerc et al., “Drug prevention of restenosis after angioplasty: an update”,Elsevier Science,(1995), pp. 722-724.
Lefkovits et al., “Pharmacological Approaches for the Prevention of Restenosis After Percutaneous Coronary Intervention”,Progress in Cardiovascular Disease,(1997), vol. 40, No. 2, pp. 141-158.
Hamon et al., “Restenosis after coronary angioplasty”,European Heat Journal,(1995), vol. 16, pp. 33-48.
Gottsauner-Wolf et al., “Influence of local delivery of the protein tyrosine kinase receptor inhibitor tyrphostin-47 on smooth-muscle cell proliferation in rat carotid balloon-injury model”,American Heart Journal,(1996), vol. 19, pp. 347-356.
Donbrow, “Microcapsules and Nanoparticles In Medicine and Pharmacy”, CRC Press, Boca Raton, Fl. pp. 347.
Shioi et al., “β-Glycerophoshate Accelerates Calcification in Cultured Bovine Vascular Smooth Muscle Cells”,Arteriosclerosis, Thrombosis and Vascular Biology,(1995), vol. 15, No. 11, pp. 2003-2009.
Paspaliaris et al., “Clodronate Inhibits Contraction and prevents the Action of L-Type Calcium Channel Antagonists in Vascular Smooth Muscle”, (1991),Journal of Bone and Mineral Research,vol. 6, No. 8, pp. 835-841.
Bellah et al., “Idiopathic arterial calcification of Infancy: Prenatal and postnatal effects of therapy in an infant”, (1992),The Journal of Pediatrics,vol. 121, No. 6, pp. 930-933.
Waller et al., “Coronary Artery and Saphenous Vein Graft Remodeling: A Review of Histologic Findings after Various Interventional Procedure—Part VI”,Clin Cardiol.,(1997), vol. 20, pp. 153-160.
Anderson et al., “A review of randomized trials comparing coronary angioplasty and bypass grafting”,Curr-Opin-Cardiol,(1996), vol. 11, No. 6, pp. 583-590.
Moorman et al., “Percutaneous Transluminal Coronary Angioplasty (PTCA): Long-term Outcome and Aeromedical Implications”,Aviation, Space and Environmental Medicine,(1996), vol. 67, No.10, pp. 990-996.
Laurent et al., “The arterial wall: a new pharmacological and therapeutic target”,Fundam Clin Phramacol,(1996), vol. 10, pp. 243-257.
Schwartz, “The vessel wall reaction in restenosis”,Semin-Interv-Cardiol,(1997), vol. 2, pp. 83-88.
Allaire et al, “Endothelial Cell Injury in Cardiovascular Surgery: The Intimal Hyperplastic Response”,Ann Thorac Surg,(1997), vol. 63, pp. 582-591.
Webb et al, “Inhibition of Bioprosthetic Heart Valve Calcification with Aminodiphosphonate Covalently Bound to Residual Aldehyde Groups”,Ann Thorac Surg.,(1988), vol. 46, pp. 309-316.
Wagner et al., “Contrasting Effects of Ethane-1-Hydroxy-1, 1-Diphosphonate (EHDP) on the Regression of two types of Dietary-Induced Atherosclerosis”,Atherosclerosis,(1977), vol. 27, pp. 419-435.
Daoud et al., “The effect of ethane-1-hydroxy-1, 1-diphosphonate (EHDP) on necorsis of atherosclerotic lesions”,Atherosclerosis,(1987), vol. 67, pp. 41-48.
Walsh et al., “Molecular strategies to inhibit restenosis: modulation of the vascular myocyte phenotype”,Semin Intervent Cardiol,(1996), vol. 1, pp. 173-179.
Hermann et al., “Pharmacological Approaches to the prevention of Restenosis Following Angioplasty”,Drug,(1993), vol. 46, No. 1, pp. 18-52.
Ylitalo, 2002, “Bisphosphonates and atherosclerosis”General Pharmacology35:287-296.
Kramsch et al., “The Effect of Agents Interfering with Soft Tissue Calcification and Cell Proliferation on Calcific Fibrous-Fatty Plaques in Rabbits”, Circulation Research, (1978), vol. 42, No. 4, pp. 562-570.
Fleisch, “Bisphophonates in bone disease”, Parthenon Publishing Group Inc., (1997), pp. 184-210.
Mak, et al., “Clinical Trials to Prevent Restenosis after Percutaneous Coro
Danenberg Haim
Golomb Gershon
Gollamudi Sharmila S.
Kunz Gary
Morgan & Finnegan , LLP
Yissum Research Development Company of the Hebrew University of
LandOfFree
Method of treating restenosis using bisphosphonate... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating restenosis using bisphosphonate..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating restenosis using bisphosphonate... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3561511